Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of ... Read More
Lilly to launch pragmatic study of Covid-19 drug candidate bamlanivimab in New Mexico
Eli Lilly and Company (Lilly) has revealed plans to launch a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with Covid-19, in partnership with ... Read More
Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study
Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) ... Read More
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly ... Read More
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, ... Read More